吉非贝齐对某些血液学参数影响的一项初步研究。

A pilot study of the effect of Gemfibrozil on some haematological parameters.

作者信息

O'Brien J R, Etherington M D, Shuttleworth R D, Adams C M, Middleton J E, Goodland F C

出版信息

Thromb Res. 1982 May 15;26(4):275-9. doi: 10.1016/0049-3848(82)90292-4.

Abstract

In a double-blind 13 week study the effects of Gemfibrozil were compared with placebo. Gemfibrozil was given to 10 patients with evidence of severe atherosclerosis; four similar patients acted as controls. As expected, in the treated group, total cholesterol and triglycerides decreased significantly and HDL cholesterol increased. The Fibrinogen did not change although the ESR increased markedly and the heparin neutralizing activity (HNA) of the plasma decreased (p = 0.01). The antithrombic activity increased. The change in the HNA correlated weakly to the total cholesterol both before and during treatment. These findings show that some of the effects of Gemfibrozil on atherosclerotic humans are similar to those of Clofibrate but others are different.

摘要

在一项为期13周的双盲研究中，比较了吉非贝齐与安慰剂的效果。将吉非贝齐给予10名有严重动脉粥样硬化证据的患者；4名情况相似的患者作为对照。如预期的那样，在治疗组中，总胆固醇和甘油三酯显著降低，高密度脂蛋白胆固醇升高。尽管血沉显著升高且血浆肝素中和活性（HNA）降低（p = 0.01），但纤维蛋白原未发生变化。抗血栓活性增加。治疗前和治疗期间，HNA的变化与总胆固醇的相关性较弱。这些发现表明，吉非贝齐对动脉粥样硬化患者的某些作用与氯贝丁酯相似，但其他作用则不同。